Elotuzumab and Weekly Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Without Transplant Intent: A Phase 2 Measurable Residual Disease-Adapted Study.
暂无分享,去创建一个
A. Jakubowiak | J. Zonder | T. Karrison | A. Stefka | S. Gurbuxani | A. Kin | A. Major | A. Kansagra | B. Derman | J. Jasielec | D. Grinblatt | L. Anderson | S. Rayani | Sunil Narula | K. Jiang